Aa
Presentation on Arc-520
http://www.twitlonger.com/show/n_1sktde6
What it means ? That you will need some antiviral drug to take together with ACR-520 ?
fact, ARWR believes that some novel agents may be ready to partner with ARC520 as early as H2 15 (perhaps Novira).
Here's the article for those who can't get to the link:
RBC $ARWR Arrowhead Research Corp. (NASDAQ: ARWR)
COO Bruce Given presented.
COO Bruce Given suggested topline data from Phase 2a ARC-520 study will come in Q2:15, probably after EASL, as some
holidays prolonged enrollment into perhaps January and with longer blinded period of 85 days this implies with math, data
mid or later April perhaps by our estimate.
What's becoming more clear is management further emphasized that their strategy could include partnering and they want
to be “agnostic” to collaboration partners, such as with other known compounds (Assembly, Novira, Oncore, or big pharma
like BMY which is working on HBV internally) - that is, they are aiming for a “Pharmasset-like” open collaborative model. In
fact, ARWR believes that some novel agents may be ready to partner with ARC520 as early as H2 15 (perhaps Novira).
Obviously, a collaboration could be a key catalyst if that happens, in our view.
For ARC-AAT, first patient was dosed this week; data should come by YE:15, where 80–90% knockdown is possible (~90%
was seen in normal monkeys, and 100% not feasible due to 5–10% systemic presence of AAT not in liver).
RBC $ARWR Arrowhead Research Corp. (NASDAQ: ARWR)
COO Bruce Given presented.
COO Bruce Given suggested topline data from Phase 2a ARC-520 study will come in Q2:15, probably after EASL, as some
holidays prolonged enrollment into perhaps January and with longer blinded period of 85 days this implies with math, data
mid or later April perhaps by our estimate.
What's becoming more clear is management further emphasized that their strategy could include partnering and they want
to be “agnostic” to collaboration partners, such as with other known compounds (Assembly, Novira, Oncore, or big pharma
like BMY which is working on HBV internally) - that is, they are aiming for a “Pharmasset-like” open collaborative model. In
fact, ARWR believes that some novel agents may be ready to partner with ARC520 as early as H2 15 (perhaps Novira).
Obviously, a collaboration could be a key catalyst if that happens, in our view.
For ARC-AAT, first patient was dosed this week; data should come by YE:15, where 80–90% knockdown is possible (~90%
was seen in normal monkeys, and 100% not feasible due to 5–10% systemic presence of AAT not in liver).
Intending partnership with Novira, hope this 'll facilitate the drug to the market.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
